October 11: The Week in Cancer News
Expanded dependent coverage improves cancer outcomes in young adults, and breast cancer treatment can lead to faster cell aging.
Progress Against Cancer
Expanded dependent coverage improves cancer outcomes in young adults, and breast cancer treatment can lead to faster cell aging.
The PI3K inhibitor is approved as part of combination therapy for certain patients whose breast cancer recurred on or after endocrine therapy. The U.S. Food and Drug Administration (FDA) approved inavolisib (Itovebi), in combination...
Study finds people who receive brain radiation often recover cognitive abilities over time, and report details breast cancer trends.
The immunotherapy is now approved to treat certain lung cancers before and after surgery. The U.S. Food and Drug Administration (FDA) has approved neoadjuvant nivolumab (Opdivo) with platinum-containing chemotherapy, followed by adjuvant nivolumab alone,...
Adding MRI to prostate screening can help limit overdiagnosis, and breast cancer patients who smoke have a higher risk of radiotherapy-related lung cancer.
The accelerated approval of selpercatinib for certain patients with thyroid cancer was converted to a full approval. The U.S. Food and Drug Administration (FDA) has granted full approval to selpercatinib (Retevmo) for patients 2...
The EGFR inhibitor osimertinib is now available as a monotherapy for certain patients with locally advanced, unresectable non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved osimertinib (Tagrisso) to treat...
The AACR spotlights cancer advances and challenges in new report, and the FDA approves second CDK 4/6 inhibitor to reduce risk of recurrence in early-stage breast cancer.
The CD38-targeted antibody was approved for patients who are ineligible for stem cell transplant. The U.S. Food and Drug Administration (FDA) has approved isatuximab-irfc (Sarclisa) in combination with VRd (a regimen consisting of bortezomib...
Amivantamab with carboplatin and pemetrexed was approved for some advanced non-small cell lung cancers that progressed on or after EGFR inhibition. The U.S. Food and Drug Administration (FDA) has approved amivantamab-vmjw (Rybrevant) plus the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now